dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

August 31, 2021: AC Immune SA

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11

First evidence of clinical activity in tau-targeting monoclonal antibody in MMSE 16-21 (mild-to-moderate) AD population

Partner Genentech to continue open label portion of the study and plans to submit top line results for presentation at November CTAD 2021 congress

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, has informed the Company that Lauriet, a placebo-controlled Phase 2 study evaluating the safety and efficacy of the investigational anti-tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), met one of its co-primary endpoints, ADAS-Cog11. The second co-primary endpoint, ADCS-ADL, was not met. Safety data showed that semorinemab is well tolerated with an acceptable safety profile and no unanticipated safety signals.

Please read the whole article here

AC Immune SA, News 2021
August 31, 2021: CureVac AG
September 2, 2021: AC Immune SA

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz